Scarica l'app Stockscreener
2.02
5.61%
-0.12
Hookipa Pharma Inc Borsa (HOOK) Ultime notizie
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 26% - Simply Wall St
RBC downgrades HOOKIPA Pharma stock to Sector Perform as restructuring resets pipeline to preclinical - Investing.com
HOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shifts By Investing.com - Investing.com South Africa
Fmr LLC Has $1.47 Million Holdings in Hookipa Pharma Inc (NASDAQ:HOOK) - Defense World
HOOKIPA Pharma's SWOT analysis: stock faces challenges amid pipeline shifts - Investing.com
Hookipa Pharma stock hits 52-week low at $2.07 amid market challenges - Investing.com
HOOK (HOOKIPA Pharma) COGS-to-Revenue : 0.00 (As of Sep. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) GF Value Rank : 2 (As of Nov. 25, 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) Debt-to-Equity : 0.04 (As of Sep. 2024) - GuruFocus.com
JMP Securities Has Lowered Expectations for Hookipa Pharma (NASDAQ:HOOK) Stock Price - Defense World
Hookipa Pharma price target lowered to $7 from $24 at JMP Securities - Yahoo Finance
Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program - Yahoo Finance
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com Canada
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges By Investing.com - Investing.com South Africa
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartzy
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - The Manila Times
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker - GlobeNewswire
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline - GlobeNewswire
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
HOOKIPA Pharma Doses First Patients with Eseba-vec as - GlobeNewswire
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):